ReviewJournal of clinical and experimental hepatology2014
Resection for hepatocellular carcinoma.
Review in Journal of clinical and experimental hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Preoperative Phenacetin Metabolism Test in the Prediction of Postoperative Liver Dysfunction of Patients with Hepatocellular Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2017Trial
- The Role of Macrophages in Hepatocellular Carcinoma and Their Therapeutic Potential.International journal of molecular sciences · 2024Review
- Review
- Hepatocellular carcinoma in old age: are there any benefits of liver resection in old age?Annals of surgical treatment and research · 2020Article
- Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center.PloS one · 2020Article
- Selective occlusion of the hepatic artery and portal vein improves liver hypertrophy for staged hepatectomy.World journal of surgical oncology · 2019Article
- Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation.Hepatobiliary surgery and nutrition · 2018Article
- MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation.Oncology letters · 2018Article
- Article
- Prediction of early recurrence of hepatocellular carcinoma within the Milan criteria after radical resection.Oncotarget · 2017Article
- HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations?Visceral medicine · 2016Review
- Hepatocellular carcinoma: Where are we?World journal of experimental medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular Carcinoma (HCC) continues to present major challenges in management, which is further complicated by the presence of associated chronic liver disease. Key issues in surgical resection of HCC include the site, size, and number of lesions, the severity of the chronic liver disease, and the size of the functional liver remnant. De novo HCC in the absence of chronic liver disease can be treated by major liver resection with little risk of postoperative liver failure. Liver resection can also be used a bridge to liver transplantation as it affords the possibility of determining the pathologic grade of the tumortumor and its invasiveness, and thereby the prognosis. This review summarizes the current treatment approaches to surgical resection for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.